SEATTLE--(BUSINESS WIRE)-- Dendreon Corporation (NASDAQ:DNDN) today announced that management will host a conference call on Wednesday, November 2, 2011 at 4:30 p.m. ET to review the third quarter 2011 financial results.
Access to the discussion may be obtained as follows:
4:30 p.m. ET / 1:30 p.m. PT
|Date:||November 2, 2011|
1-877-548-9590 (domestic) or +1-720-545-0037 (international);
www.dendreon.com (homepage and investor relations section)
A recorded rebroadcast will be available for interested parties unable to participate in the live conference call by dialing 800-585-8367 or +1-404-537-3406 for international callers; the conference ID number is 15978924. The replay will be available from 7:30 p.m. ET on November 2 until 11:59 p.m. ET on November 9. In addition the webcast will be archived for on-demand listening for 30 days at www.dendreon.com.
Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development, commercialization and manufacturing of novel therapeutics. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy product candidates designed to stimulate an immune response in a variety of tumor types. Dendreon’s first product, PROVENGE® (sipuleucel-T), was approved by the FDA in April 2010. Dendreon is exploring the application of additional ACI product candidates and small molecules for the potential treatment of a variety of cancers. The Company is headquartered in Seattle, Washington and is traded on the NASDAQ Global Market under the symbol DNDN. For more information about the Company and its programs, visit http://www.dendreon.com/.
V.P. Corporate Communications & Investor Relations
Katherine Stueland, 206-829-1522
KEYWORDS: United States North America Washington
INDUSTRY KEYWORDS: Health Biotechnology Oncology